| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
AWcorna, originally termed ARCoV[2] and also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science.[3] In contrast to other mRNA COVID-19 vaccines, such as those by Pfizer-BioNTech and Moderna, this vaccine primarily targets the SARS-CoV-2 receptor-binding domain of the spike protein, rather than the entire spike protein.[4] It is approved for Phase III trials in China,[5] Mexico,[6] Indonesia,[7] and Nepal.[8]
It was granted emergency use approval in Indonesia in September 2022.[9]
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ Liu X, Li Y, Wang Z, Cao S, Huang W, Yuan L, et al. (August 2022). "Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults". Cell Research. 32 (8): 777–780. doi:10.1038/s41422-022-00681-3. PMC 9197092. PMID 35701541.
- ^ "SARS-CoV-2 mRNA vaccine". go.drugbank.com. Retrieved 10 April 2021.
- ^ Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, et al. (March 2022). "Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial". The Lancet. Microbe. 3 (3): e193–e202. doi:10.1016/S2666-5247(21)00280-9. PMC 8786321. PMID 35098177.
- ^ Ma J (22 July 2021). "Domestic clinical trials planned for China's mRNA Covid-19 vaccine". South China Morning Post. Retrieved 23 July 2021.
- ^ "Mexico to start late-stage clinical trial for China's mRNA COVID-19 vaccine". Reuters. 11 May 2021. Retrieved 14 May 2021.
- ^ Pinghui Z (1 September 2021). "Indonesia, Mexico approve phase 3 trials of Chinese mRNA vaccine hopeful". South China Morning Post. Retrieved 1 September 2021.
- ^ "Nepal approves late-stage trials for Chinese mRNA vaccine candidate". Reuters. 27 August 2021. Retrieved 28 August 2021.
- ^ Widianto S, Liu R (30 September 2022). "A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia". Reuters. Retrieved 18 November 2022.